Bifidobacterium bifidum: The First-Discovered Bifidobacterium & Infant-Adapted Strain

Bifidobacterium bifidum is the species that started an entire genus. Isolated in 1900 by the French pediatrician Henri Tissier from the stool of a healthy breastfed infant, it is the type species of the Bifidobacterium genus — the reference organism against which every other Bifidobacterium has since been compared. More than a century later, B. bifidum remains one of the most-studied probiotic species in early-life microbiome research, and it continues to appear in adult multi-strain formulations for its distinctive adhesion biology and immune-signaling profile.

The short answer

Bifidobacterium bifidum is one of the foundational Bifidobacterium species of the human colon and the first member of the genus ever isolated and described. It was identified in 1900 by Henri Tissier of the Pasteur Institute, who recovered it from the stool of a healthy breastfed infant and named it for the distinctive Y-shaped (“bifid”) branching of the rods under microscopy. For decades, every Bifidobacterium species discovered afterward was compared back to B. bifidum as the genus type strain.

Modern research has examined B. bifidum across several directions: digestive comfort in adults with irritable bowel symptoms (most notably the MIMBb75 strain studied by Guglielmetti and colleagues), pre-term neonatal supportive-care literature, and immune-signaling research with strains like the Korean-origin BGN4. B. bifidum is notable among Bifidobacteria for its strong adhesion to the colonic mucus layer — a property that has made it a frequent subject of mechanistic studies into how probiotic species interact with the intestinal lining.

What is Bifidobacterium bifidum?

Bifidobacterium bifidum is a Gram-positive, anaerobic bacterium and the type species of the Bifidobacterium genus — meaning it is the reference organism that defines the genus taxonomically. The species sits alongside B. longum, B. breve, B. lactis, and B. animalis as one of the most extensively studied Bifidobacteria in human gut research. Like its relatives, B. bifidum is non-spore-forming, ferments sugars rather than producing the metabolites associated with potentially harmful gut bacteria, and prefers the low-oxygen environment of the colon.

What distinguishes B. bifidum from many of its sibling species is its biology at the mucus layer. The species expresses surface proteins and enzymes that allow it to bind to the mucin glycoproteins that line the colon — the same layer that protects the underlying epithelium from direct contact with luminal contents. This adhesion biology is one reason B. bifidum has been used in mechanistic research on probiotic-host interaction, and it is part of why the species appears in adult multi-strain formulations even though its absolute abundance declines past infancy.

The species name — bifidum, from the Latin for “split in two” — refers to the characteristic Y-shaped or forked cell morphology that Tissier described in his 1900 isolation report. That branching shape was the visible feature that distinguished his new bacterium from the lactobacilli and clostridia already known at the time, and it gave the entire genus its name. Modern microbiology relies on molecular methods rather than cell shape for species identification, but the “bifid” morphology is still part of how Bifidobacterium colonies are described in older texts and how the genus is introduced in microbiology teaching.

Where B. bifidum comes from

B. bifidum is one of the species transferred to infants in the earliest weeks of life and one of several Bifidobacteria that dominate the breastfed-infant colon during the first months. It is acquired through two main pathways:

• Vaginal birth. Passage through the birth canal exposes the infant to the mother’s vaginal and perineal microbiota, which contributes a foundational population of Bifidobacterium and Lactobacillus species. Microbiome studies have observed differences in the infant gut microbiota between vaginal and cesarean deliveries during the first months, with many of these differences narrowing over the first year of life.
• Breast milk and human milk oligosaccharides. Breast milk is now understood to carry both live bacteria and a class of complex sugars — human milk oligosaccharides, or HMOs — that human infants cannot digest but that B. bifidum and other infant-adapted Bifidobacteria can ferment. This selective feeding helps Bifidobacterium species dominate the breastfed-infant colon and is the molecular reason these species thrive in early life.

Outside of infancy, B. bifidum can be recovered in smaller amounts from healthy adults, from fermented dairy products, and from commercially manufactured probiotic supplements. Its share of the total adult microbiome is typically lower than that of B. longum or B. lactis, which is part of why it is most often included in multi-strain blends rather than sold as a stand-alone adult supplement.

Key clinical strains

As with every probiotic species, the relevant unit for research is the strain — the genetically specific lineage — not the species as a whole. Three B. bifidum strains appear most often in the published clinical literature:

• B. bifidum MIMBb75. Studied by Guglielmetti and colleagues in adult irritable-bowel research, MIMBb75 is the most-cited B. bifidum strain in modern functional-bowel research. The 2011 Guglielmetti trial examined daily MIMBb75 supplementation over four weeks in adults with IBS, with patient-reported symptom outcomes as the primary endpoint.
• B. bifidum PRL2010. A strain extensively characterized at the genomic and biochemical level, PRL2010 has been used in mechanistic research on Bifidobacterium adhesion to the colonic mucus layer and in investigations relevant to colorectal-cancer microbiome research. It is more often a research tool than a consumer-supplement strain.
• B. bifidum BGN4. A Korean-origin strain used in immune-signaling research, particularly in studies relevant to atopic and allergic conditions (Yoon and colleagues, 2014). BGN4 has been studied as both a single strain and as a component of multi-strain formulations.

Most consumer probiotic labels list only the species name (“Bifidobacterium bifidum”) and do not specify the strain code. For alignment with the published research, look for products that name the strain explicitly. The distinction matters: two B. bifidum strains can share a species name while differing in their adhesion properties, fermentation profile, and how they have been studied in trials. A product labeled simply “B. bifidum” is not necessarily inferior, but it cannot be assumed to deliver the specific outcomes of the MIMBb75 or BGN4 research literatures.

What the research has explored

B. bifidum appears in a substantial published literature spanning more than a century, starting with Tissier’s original 1900 isolation report and continuing through modern molecular and clinical investigations. The studies referenced below are research investigations of specific strains in specific contexts; outcomes do not generalize to every B. bifidum-containing product, and none of this constitutes treatment claims for any disease.

Irritable bowel research. Guglielmetti and colleagues (2011) examined B. bifidum MIMBb75 in adults with irritable bowel syndrome over a four-week supplementation period, with patient-reported global symptom relief and quality-of-life scales as the primary endpoints. The investigation is one of the more frequently cited single-strain Bifidobacterium trials in the functional-bowel literature.

Microbiome and gut-disease research. The Lloyd-Price and colleagues (2017) review of strains, functions, and dynamics in the human microbiome project provides foundational context for how Bifidobacterium species — including B. bifidum — are distributed across healthy and disease-associated cohorts. This body of work is observational microbiome science rather than supplementation research.

Pre-term neonatal research. B. bifidum has been studied as part of multi-strain probiotic mixtures examined in pre-term neonatal supportive care, with the primary endpoint of interest in many of these trials being necrotizing enterocolitis (NEC). The trials were conducted in NICU settings under physician oversight and are not a basis for parents to self-supplement pre-term infants at home.

Immune-signaling research. Yoon and colleagues (2014) examined B. bifidum BGN4 in research relevant to immune signaling and atopic conditions, contributing to a broader body of work on Korean-origin Bifidobacterium strains in pediatric immunology research.

The ISAPP 2014 consensus statement (Hill et al.) on the scope and appropriate use of the term “probiotic” provides the definitional framework that the entire field operates within and is the reference document for serious discussion of probiotic research. The Mattarelli and colleagues 2008 review on the taxonomy and classification of the Bifidobacterium genus is the standard taxonomic reference, including the historical placement of B. bifidum as the type species.

Typical dosing in research

Dosing in B. bifidum trials varies by population, strain, and the question being investigated, but a few patterns recur:

• Single-strain adult research, such as the MIMBb75 IBS trial, used B. bifidum doses in the range of 1 billion CFU per day over four to eight weeks.
• Multi-strain blends that include B. bifidum typically allocate the species 1–5 billion CFU per daily dose, with the remainder of the total CFU distributed across the other strains.
• Infant research used substantially lower per-strain doses, typically in the hundred-million-to-low-billion CFU range, in NICU and pediatric clinical settings under physician oversight.

For consumer adult formulations, total CFU counts of 10–100 billion across all strains are common; the per-strain B. bifidum count within those blends typically sits in the lower billions. Higher CFU is not automatically better — the strain selection, the formulation’s stability and delivery system, and whether the CFU is guaranteed at end of shelf life all matter more than the headline number on the label.

Safety in infants and adults

B. bifidum is one of the most extensively studied probiotic species in the published literature, with a research history that spans more than a century. It is generally considered safe for healthy adults and has been used in both consumer products and clinical investigations across decades. The species has the same broad safety profile as other Bifidobacteria of the human colon.

Several caveats apply:

• Probiotics in immunocompromised individuals, those with central venous catheters, or anyone with serious underlying illness should only be used under medical supervision. Case reports of bacteremia with probiotic organisms exist in these populations.
• Probiotics for pre-term or critically ill neonates are a medical decision, not a consumer one. The research that exists has been conducted in NICU settings under physician oversight.
• Healthy adults generally tolerate B. bifidum well at recommended consumer doses. Mild and transient digestive adjustment (gas, looser stools) in the first few days is common when introducing any new probiotic.

As with any supplement, anyone who is pregnant, nursing, taking prescription medications, or managing a medical condition should discuss probiotic use with their healthcare provider before starting.

B. bifidum vs. other Bifidobacterium species

The Bifidobacterium genus contains several species that appear repeatedly in adult and pediatric probiotic formulations. Each has a slightly different ecological niche and research footprint:

• B. bifidum — the type species of the genus, notable for its strong adhesion to the colonic mucus layer and its long research history dating back to Tissier’s 1900 isolation. Studied in adult IBS research (MIMBb75) and immune-signaling work (BGN4).
• B. breve — most heavily studied in pediatric and pre-term neonatal contexts, particularly with the M-16V strain. Its share of the microbiome peaks in infancy and declines with age. See our Bifidobacterium breve profile for more.
• B. longum — one of the longest-resident species in the adult colon and a near-universal inclusion in adult multi-strain formulations. Studied for fermentation, microbial diversity, and gut-brain signaling. See our Bifidobacterium longum profile.
• B. lactis — the most-studied Bifidobacterium for adult digestive regularity and transit time, with the BB-12 strain being one of the most-researched probiotic strains in any genus. See our Bifidobacterium lactis profile.

A useful way to think about the four: B. bifidum is the genus type species and is studied most for its mucus-layer adhesion; B. breve is the infant-associated species; B. longum is the lifelong colonic resident; and B. lactis is the everyday regularity workhorse in adult research. A premium multi-strain formula does not have to contain all four to be effective, but a blend that includes two or more Bifidobacterium species generally provides broader genus coverage than a single-species product.

Who might benefit most

B. bifidum appears most often in formulations and research aimed at:

• Adults looking for broad Bifidobacterium diversity in their daily probiotic, beyond the typical B. lactis/B. longum base
• Adults with general digestive-comfort considerations, given the MIMBb75 IBS research history
• People rebuilding the Bifidobacterium share of their microbiome after antibiotic disruption
• Pediatric supplementation under physician guidance — see our best probiotic for babies guide for context on infant-targeted products

For a glossary of the terms used here — CFU, strain vs. species, type species, postbiotics, prebiotics — see our gut health glossary.

The bottom line

Bifidobacterium bifidum is the species that started the genus — isolated from a healthy breastfed infant in 1900 by Henri Tissier, named for its distinctive Y-shaped morphology, and used ever since as the taxonomic reference for every Bifidobacterium described afterward. Its research footprint is broad: adhesion biology and mucus-layer interaction, adult IBS research with the MIMBb75 strain, immune-signaling work with BGN4, and a century of pediatric and neonatal investigation. B. bifidum remains a meaningful inclusion in adult multi-strain probiotic formulations and one of the better-characterized members of the Bifidobacterium genus. As with any probiotic, decisions for infants, pre-term babies, or anyone with significant medical considerations should be made in consultation with a qualified healthcare provider.